Sigyn Therapeutics (SIGY) Gains from Investment Securities (2023 - 2025)

Sigyn Therapeutics has reported Gains from Investment Securities for 3 years, with the latest figure at $17505.0 in Q2 2025.

• Quarterly Gains from Investment Securities changed N/A year-over-year to $17505.0 in Q2 2025, while the trailing twelve-month figure through Sep 2025 was -$21440.0 (up 93.14% YoY) and the FY2024 annual result came in at -$38945.0, up 88.97% from the prior year.
• Gains from Investment Securities improved to $17505.0 in Q2 2025 per SIGY's latest filing, from -$63715.0 in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $24770.0 in Q3 2024 and troughed at -$208556.0 in Q2 2023.
• A 3-year average of -$53486.4 and a median of -$15806.0 in 2023 frame the typical range for Gains from Investment Securities.
• The widest YoY moves for Gains from Investment Securities: up 1064.94% in 2024, down 49.45% in 2024.
• Over 3 years, Gains from Investment Securities stood at -$126036.0 in 2023, then soared by 49.45% to -$63715.0 in 2024, then jumped by 127.47% to $17505.0 in 2025.
• According to Business Quant data, Gains from Investment Securities over the past three periods registered $17505.0, -$63715.0, and $24770.0 for Q2 2025, Q4 2024, and Q3 2024 respectively.